Targeting the inhibition of the LCK-14-3-3ζ-TRPM8 axis to impair oncogene function of both TRPM8 and LCK may enhance tumor sensitivity to therapeutics, allowing for potential pharmacological targeting for anticancer therapy. Here, TRPM8 is linked to neoplasm.